Bionano Genomics Inc Stock Price, News & Analysis

Bionano Genomics (NASDAQ: BNGO) has completed its previously announced public offering, raising $10 million through the sale of 5,000,000 shares of common stock at $2.00 per share. The offering included Series E warrants (5-year expiration) and Series F warrants (18-month expiration) to purchase up to an additional 5 million shares each at a $2.00 exercise price.

If all warrants are fully exercised, the company could receive additional gross proceeds of approximately $20 million. H.C. Wainwright & Co. served as the exclusive placement agent. The company plans to use the net proceeds for working capital and general corporate purposes.

Bionano Genomics (NASDAQ: BNGO) has announced the pricing of a $10 million public offering consisting of 5,000,000 shares of common stock (or equivalents) and accompanying warrants at $2.00 per share. The offering includes Series E warrants with a 5-year term and Series F warrants with an 18-month term, both with a $2.00 exercise price.

If all warrants are fully exercised, the company could receive additional gross proceeds of approximately $20 million. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is expected to close around September 17, 2025, with proceeds intended for working capital and general corporate purposes.

Bionano Genomics (NASDAQ: BNGO) announced the publication of multiple studies in Methods in Molecular Biology highlighting the advantages of optical genome mapping (OGM) in chromoanagenesis research. Chromoanagenesis, a catastrophic genomic event associated with complex cancer characteristics and poor prognosis, has been difficult to detect using traditional methods.

The publication includes four chapters demonstrating OGM's application in various cancer types, including acute myelogenous leukemia (AML), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). The studies showcase OGM's ability to provide high-resolution, genome-wide views of structural variants crucial for understanding chromoanagenesis in cancer development.

Bionano Genomics (NASDAQ:BNGO) announced that CMS has posted a preliminary payment determination for a new Category I CPT code (81354) covering optical genome mapping (OGM) for constitutional genetic disorders. The payment is set at $1,263.53, which is higher than comparable microarray codes by $363.53 and $103.53 respectively.

This represents the second CPT code for OGM, alongside code 81195 for hematologic malignancy analysis. The pricing will become effective on January 1, 2026, and will apply to Bionano Laboratories' OGM-Dx™ Postnatal and Prenatal Whole Genome SV tests, which are used for detecting structural and copy number variations in genetic disorders.

Bionano Genomics (Nasdaq: BNGO) announced that its CEO Erik Holmlin, PhD, will present at the H.C. Wainwright 27th Annual Global Investment Conference. The presentation is scheduled for September 8th, 2025, from 3:00 p.m. to 3:30 p.m. ET.

Investors can access the presentation through a webcast, and a replay will be available on Bionano's investor relations website at ir.bionano.com for a minimum of 30 days following the conference.

Bionano Genomics (Nasdaq: BNGO) reported Q2 2025 financial results showing a strategic shift towards focusing on routine users of optical genome mapping (OGM) and VIA™ software. Total revenue was $6.7 million, down 13% year-over-year, though consumables and software revenues increased 16%. The company achieved a significant improvement in gross margin to 52% from 33% in Q2 2024.

Key operational metrics include 7,233 nanochannel array flowcells sold (up 17% YoY), 7 new OGM system installations, reaching a total installed base of 378 systems. Operating expenses were reduced by 42% to $11.3 million. The company maintains its full-year 2025 revenue guidance of $26.0-$30.0 million and expects Q3 2025 revenue of $6.7-$7.2 million, with cash runway extending into Q1 2026.

Bionano Genomics (NASDAQ:BNGO) announced a significant peer-reviewed publication demonstrating the effectiveness of their optical genome mapping (OGM) technology in detecting oncogenic structural variants in infant and toddler T-cell acute lymphoblastic leukemia (T-ALL).

The study, conducted across multiple French pediatric centers, analyzed 27 T-ALL cases in children under 3 years. Key findings include: 33% of cases carried previously uncharacterized NKX2 gene rearrangements, distinct genomic profiles compared to older children, and a 75.4% five-year overall survival rate. The research demonstrated OGM's ability to identify prognostic subgroups and detect complex genetic rearrangements in a single workflow, potentially improving disease classification and management.

Bionano Genomics (Nasdaq: BNGO) announced that CEO Erik Holmlin, PhD, will present at the Canaccord Genuity 45th Annual Growth Conference on August 13, 2025. The presentation is scheduled for 3:00 p.m. to 3:25 p.m. ET.

Investors can access the presentation through a webcast, and a replay will be available on the company's investor relations website for at least 30 days following the event.

Bionano Genomics (NASDAQ: BNGO) has announced significant upgrades to its software platforms VIA™ 7.2 and Solve™ 3.8.3, along with enhancements to its Stratys™ Compute server. The updates focus on improving the analysis of optical genome mapping (OGM), microarray, and NGS data.

Key improvements include AI-powered workflow transformation for constitutional genetic disorders, an 18% expansion of the structural variants control database, and the ability to double the number of cancer samples analyzed per week. The software releases will initially be available to 20 early access users, with broad commercial release expected in Q4 2025.

The upgrades introduce significance associated with phenotype (SAP) scoring for OGM data and enhance the system's ability to learn from historical lab results, improving interpretation speed and accuracy.